文献速递泌尿男性生殖肿瘤

安慰剂交叉至达罗他胺对非转移性前列腺癌患者总生存期的影响:随机3期ARAMIS研究的敏感性分析

Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study.
PubMed 文献 · Eur J Cancer · 2023-09-17

ARAMIS研究中,非转移性去势抵抗性前列腺癌患者随机接受达罗他胺600mg每日两次(n=955)或安慰剂(n=554),揭盲后170例(30.7%)安慰剂组患者交叉至达罗他胺。最终意向性治疗分析显示达罗他胺显著改善总生存期(HR 0.69,95%CI 0.53-0.88,P=0.003),校正交叉后获益增大(RPSFT HR 0.68,IPE HR 0.66,OS校正删失HR 0.59,IPCW HR 0.63)。

要点

  • 揭盲后30.7%安慰剂组患者交叉至达罗他胺,校正交叉后达罗他胺降低死亡风险最高达41%。
  • 最终意向性治疗分析中达罗他胺较安慰剂显著改善总生存期(HR 0.69,95%CI 0.53-0.88)。
  • 达罗他胺良好安全性维持,包括交叉患者。

核心结论

  • 校正交叉后,达罗他胺使非转移性去势抵抗性前列腺癌患者的死亡风险最高降低41%。
  • 达罗他胺对总生存期的影响可能在原始意向性治疗分析中被低估。

研究设计与样本

  • 随机3期ARAMIS研究(NCT02200614),非转移性去势抵抗性前列腺癌患者随机接受口服达罗他胺600mg每日两次(n=955)或安慰剂(n=554)。
  • 预设敏感性分析采用秩保持结构失效时间(RPSFT)和迭代参数估计(IPE)法。
  • 事后敏感性分析采用总生存期校正删失法和逆概率删失加权(IPCW)法,对基线睾酮和前列腺特异性抗原进行加权。

主要发现

  • 揭盲后,554例安慰剂组患者中170例(30.7%)交叉至达罗他胺。
  • 最终总生存期意向性治疗分析(揭盲后中位11.2个月)显示,达罗他胺较安慰剂显著改善总生存期31%(HR 0.69,95%CI 0.53-0.88;P=0.003)。
  • 校正交叉的RPSFT分析HR 0.68(95%CI 0.51-0.90;P=0.007),IPE分析HR 0.66(95%CI 0.51-0.84;P<0.001)。
  • 总生存期校正删失法HR 0.59(95%CI 0.45-0.76),IPCW法HR 0.63(95%CI 0.48-0.81)。
  • 达罗他胺良好的安全性特征得以维持,包括交叉患者。

关键数值与推荐

  • 最终意向性治疗分析:达罗他胺较安慰剂改善总生存期HR 0.69(95%CI 0.53-0.88;P=0.003)。
  • RPSFT分析:HR 0.68(95%CI 0.51-0.90;P=0.007)。
  • IPE分析:HR 0.66(95%CI 0.51-0.84;P<0.001)。
  • 总生存期校正删失法:HR 0.59(95%CI 0.45-0.76)。
  • IPCW法:HR 0.63(95%CI 0.48-0.81)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase 3 ARAMIS study (NCT02200614), darolutamide significantly improved metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Following the primary analysis, the study was unblinded, and placebo recipients were permitted to cross over to open-label darolutamide. Despite crossover, darolutamide significantly improved overall survival (OS). We conducted sensitivity analyses to estimate the effect of placebo-darolutamide crossover on OS. METHODS: Patients with nmCRPC were randomised to oral darolutamide 600 mg twice daily (n = 955) or placebo (n = 554). Prespecified (rank-preserving structural failure time [RPSFT] and iterative parameter estimation [IPE]) and post hoc (OS-adjusted censoring and inverse probability of censoring weighting [IPCW], with weightings for baseline testosterone and prostate-specific antigen) sensitivity analyses were conducted. RESULTS: After unblinding, 170 of 554 placebo recipients (30.7%) crossed over to darolutamide. At the final OS intention-to-treat analysis (median 11.2 months after unblinding), darolutamide significantly improved OS by 31% versus placebo (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.53-0.88; P = 0.003). The benefit increased in the analyses adjusting for crossover is as follows: RPSFT HR 0.68, 95% CI 0.51-0.90; P = 0.007; IPE HR 0.66, 95% CI 0.51-0.84; P < 0.001; OS-adjusted censoring HR 0.59, 95% CI 0.45-0.76; IPCW HR 0.63, 95% CI 0.48-0.81. The favourable safety profile of darolutamide was maintained, including in crossover patients. CONCLUSIONS: After adjusting for crossover, darolutamide reduced the risk of death by up to 41% in patients with nmCRPC. The effect of darolutamide on OS may have been underestimated in the original intention-to-treat analysis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Shore ND, Fizazi K, Tammela TLJ, et al. Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study. Eur J Cancer. 2023. PMID: 39491396. doi:10.1016/j.ejca.2023.113342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。